Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Rain Therapeutics Inc. RAIN
$8.60
-$0.63 (-7.33%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
298367910.00000000
-
week52high
14.48
-
week52low
2.15
-
Revenue
0
-
P/E TTM
-4
-
Beta
0.07106500
-
EPS
-3.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 10:59
Описание компании
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JonesTrading | Buy | 23 июн 2022 г. | |
| Roth Capital | Buy | 02 июн 2022 г. | |
| Oppenheimer | Outperform | 01 апр 2022 г. | |
| Piper Sandler | Overweight | 18 мая 2021 г. | |
| Guggenheim | Buy | 18 мая 2021 г. | |
| HC Wainwright & Co. | Buy | 12 сент 2022 г. | |
| EF Hutton | Buy | 05 янв 2023 г. | |
| Citigroup | Buy | Buy | 23 ноя 2022 г. |
| Mizuho | Buy | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BERGER FRANKLIN M | A | 1005207 | 77000 | 22 ноя 2022 г. |
| BERGER FRANKLIN M | A | 928207 | 45000 | 21 ноя 2022 г. |
| BERGER FRANKLIN M | A | 883207 | 42881 | 08 ноя 2022 г. |
| BVF PARTNERS L P/IL | A | 341547 | 54857 | 08 ноя 2022 г. |
| BVF PARTNERS L P/IL | A | 2076085 | 685330 | 08 ноя 2022 г. |
| BVF PARTNERS L P/IL | A | 2870985 | 970171 | 08 ноя 2022 г. |
| Davis Aaron I. | A | 3422489 | 400000 | 04 ноя 2022 г. |
| Davis Aaron I. | A | 2147212 | 972212 | 04 ноя 2022 г. |
| Doebele Robert | D | 5000 | 3890 | 06 июл 2022 г. |
| Doebele Robert | A | 476827 | 3890 | 06 июл 2022 г. |
Новостная лента
Rain Therapeutics to Participate in H.C. Wainwright's 3rd Annual Precision Oncology Virtual Conference
GlobeNewsWire
14 ноя 2022 г. в 08:00
NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright's 3rd Annual Precision Oncology Conference on November 14, 2022.
Rain Therapeutics Inc. (RAIN) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 22:43
Rain Therapeutics Inc. (NASDAQ:RAIN ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Dan Ferry – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Robert Doebele – Chief Scientific Officer Richard Bryce – Chief Medical Officer Nelson Cabatuan – Senior Vice President-Finance Conference Call Participants Michael Schmidt – Guggenheim Yigal Nochomovitz – Citi Jeff Jones – Oppenheimer Mitchell Kapoor – H.C. Wainwright Soumit Roy – Jones Research Operator Greetings, and welcome to the Rain Therapeutics Third Quarter Earnings Conference Call.
Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022
GlobeNewsWire
27 окт 2022 г. в 08:00
NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results.
Rain Therapeutics Inc.'s (RAIN) CEO Avanish Vellanki on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
06 авг 2022 г. в 10:49
Rain Therapeutics Inc. (NASDAQ:RAIN ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Bob Yedid – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Nelson Cabatuan – Senior Vice President of Finance Bob Deobele – President and Chief Scientific Officer Richard Bryce – Chief Medical Officer Conference Call Participants Yige Guo – Guggenheim Sam Kurtz – Piper Sandler Jeff Jones – Oppenheimer Soumit Roy – Jones Research Tony Butler – ROTH Capital Operator Good day, and welcome to the Rain Therapeutics Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded.
Rain Therapeutics to Report Second Quarter 2022 Financial Results and Highlights of Recent Progress on August 4, 2022
GlobeNewsWire
21 июл 2022 г. в 08:00
NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter ended June 30, 2022 and highlights of recent progress on Thursday, August 4, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results.